dc.date.accessioned | 2022-11-15T07:59:00Z | |
dc.date.available | 2022-11-15T07:59:00Z | |
dc.date.created | 2022-04-13T15:51:18Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Riise, Jon Meyer, Saskia Blaas, Isaac Chopra, Adity Tran, Trung Delic-Sarac, Marina Hestdalen, Malu Lian Brodin, Ellen Elisabeth Rustad, Even Holth Dai, Ke-Zheng Vaage, John T. Nissen-Meyer, Lise Sofie Haug Sund, Fredrik Wader, Karin Fahl Bjørnevik, Anne Turid Meyer, Peter Albert Nygaard, Gro Owren König, Marton Smeland, Sigbjørn Lund-Johansen, Fridtjof Olweus, Johanna Kolstad, Arne . Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. British Journal of Haematology. 2022, 197(6), 697-708 | |
dc.identifier.uri | http://hdl.handle.net/10852/97611 | |
dc.description.abstract | B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3–6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection. | |
dc.language | EN | |
dc.publisher | Blackwell Science Ltd. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination | |
dc.title.alternative | ENEngelskEnglishRituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination | |
dc.type | Journal article | |
dc.creator.author | Riise, Jon | |
dc.creator.author | Meyer, Saskia | |
dc.creator.author | Blaas, Isaac | |
dc.creator.author | Chopra, Adity | |
dc.creator.author | Tran, Trung | |
dc.creator.author | Delic-Sarac, Marina | |
dc.creator.author | Hestdalen, Malu Lian | |
dc.creator.author | Brodin, Ellen Elisabeth | |
dc.creator.author | Rustad, Even Holth | |
dc.creator.author | Dai, Ke-Zheng | |
dc.creator.author | Vaage, John T. | |
dc.creator.author | Nissen-Meyer, Lise Sofie Haug | |
dc.creator.author | Sund, Fredrik | |
dc.creator.author | Wader, Karin Fahl | |
dc.creator.author | Bjørnevik, Anne Turid | |
dc.creator.author | Meyer, Peter Albert | |
dc.creator.author | Nygaard, Gro Owren | |
dc.creator.author | König, Marton | |
dc.creator.author | Smeland, Sigbjørn | |
dc.creator.author | Lund-Johansen, Fridtjof | |
dc.creator.author | Olweus, Johanna | |
dc.creator.author | Kolstad, Arne | |
cristin.unitcode | 185,0,0,0 | |
cristin.unitname | Universitetet i Oslo | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2017246 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British Journal of Haematology&rft.volume=197&rft.spage=697&rft.date=2022 | |
dc.identifier.jtitle | British Journal of Haematology | |
dc.identifier.volume | 197 | |
dc.identifier.issue | 6 | |
dc.identifier.startpage | 697 | |
dc.identifier.endpage | 708 | |
dc.identifier.doi | https://doi.org/10.1111/bjh.18149 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0007-1048 | |
dc.type.version | PublishedVersion | |